KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study by Swords, Ronan T., MD, PhD, FRCPI, FRCPath, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, MRCS, LRCP, FRCP, FRCPath, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, FRACP, FRCPA, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD

Get full text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study by Cortes, Jorge, Prof, Feldman, Eric, Prof, Yee, Karen, MD, Rizzieri, David, MD, Advani, Anjali S, MD, Charman, Anthony, PhD, Spruyt, Richard, BSc, Toal, Martin, FFPM, Kantarjian, Hagop, Prof

Get full text

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1... by Swords, Ronan T., MD, PhD, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD

Get full text

SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid L... by Stein, Anthony S., MD, Walter, Roland B., MD, Advani, Anjali S., MD, Ho, Phoenix A., MD, Erba, Harry P., MD, PhD

Get full text

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) by Hamilton, Betty Ky, MD, Rybicki, Lisa, MS, Advani, Anjali S., MD, Abounader, Donna, CCRP, Vu, Khoan, MD, Romee, Rizwan, MD, Zeichner, Simon B., DO, Flowers, Christopher, MD, Brown, Stacey, Bashey, Asad, MD, PhD, Viswabandya, Auro, MD, Kim, Dennis (Dong Hwan), MD, Wall, Sarah, MD, Devine, Steven M., MD, Sandhu, Karamjeet S., MD, Bachanova, Veronika, MD, PhD, McGuirk, Joseph, DO, Ganguly, Siddhartha, MD, FACP, Adekola, Kehinde, MD, Mehta, Jayesh, Ueda, Masumi, MD, de Lima, Marcos, MD, Kennedy, Vanessa, MD, Jagasia, Madan H., MD, MBBS, MS, Majhail, Navneet S., MD, MS

Get full text

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study by Kantarjian, Hagop, Prof, Thomas, Deborah, MD, Jorgensen, Jeffrey, MD, Jabbour, Elias, MD, Kebriaei, Partow, MD, Rytting, Michael, MD, York, Sergernne, RN, Ravandi, Farhad, MD, Kwari, Monica, RN, Faderl, Stefan, MD, Rios, Mary Beth, RN, Cortes, Jorge, MD, Fayad, Luis, MD, Tarnai, Robert, PhD, Wang, Sa A, MD, Champlin, Richard, MD, Advani, Anjali, MD, O'Brien, Susan, MD

Get full text

Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab by Morales, Anjali V., MD, PhD, Advani, Ranjana, MD, Horwitz, Steven M., MD, Riaz, Nadeem, BS, Reddy, Sunil, MD, Hoppe, Richard T., MD, Kim, Youn H., MD

Get full text